Human IFN-alpha I Antibody

Catalog #: MAB100801 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB100801-100
MAB100801-SP

IFN- alpha I Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN- alpha I Antibody.

1 Image

All IFN-alpha I Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IFN-alpha I Antibody Summary

Species Reactivity

Human

Specificity

Detects human IFN‑ alpha I in direct ELISAs.

Source

Monoclonal Mouse IgG₁ Clone # 995819

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Human embryonic kidney cell line HEK293-derived recombinant human IFN‑ alpha I
Met1-Asp189
Accession # P01571

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IFN‑ alpha I inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The Neutralization Dose (ND50) is typically 6-36 ng/mL in the presence of 20 pg/mL Recombinant Human IFN‑ alpha I.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IFN- alpha I Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN- alpha I Antibody. Recombinant Human IFN-alpha I reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-alpha I (20 pg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IFN-alpha I Monoclonal Antibody (Catalog # MAB100801). The ND₅₀ is typically 6-36 ng/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha I

Interferon-alpha (IFN-alpha, IFNA), also known as leukocyte interferon, represents a group of related but distinct proteins that share over 95% amino acid sequence homology. They are members of the type I interferon family which share a common cell surface receptor composed of two subunits, a 100 kDa ligand-binding subunit (IFN-alpha R2) and a 125 kDa ligand binding and signal transduction subunit (IFN-alpha R1) that is involved both in ligand binding and signal transduction. There are at least 18 different IFNA subtypes, and the major subtypes identified are IFNA1, IFNA2, IFNA8, IFNA10, IFNA14 and IFNA21.

Long Name

Interferon alpha I

Entrez Gene IDs

3451 (Human)

Alternate Names

IFNA; IFNA17; IFNalpha I; IFN-alpha I; IFN-alpha-17; IFN-alphaI; INFA; interferon alpha-17; Interferon alpha-88; Interferon alpha-I'; Interferon alpha-T; interferon alpha-WA; interferon, alpha 17; LeIF I; LEIF2C1